TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect

Wu,Hao; Wu,Hao; Guo,Xinyi; Guo,Xinyi; Jiao,Yile; Jiao,Yile; Wu,Zhenru; Wu,Zhenru; Lv,Qing; Lv,Qing

doi:10.3892/ijo.2022.5434

TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect

Authors:
- Hao Wu
- Xinyi Guo
- Yile Jiao
- Zhenru Wu
- Qing Lv
View Affiliations

Affiliations: Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: October 5, 2022 https://doi.org/10.3892/ijo.2022.5434
Article Number: 144
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer has become the leading cause of death in females. After comprehensive treatment, the lives of patients are still threatened by tumor metastasis and recurrence. Therefore, there is an urgent requirement to find an effective treatment target for breast cancer. Tripartite motif‑containing 35 (TRIM35) is a ubiquitin ligase that has an important role in the recurrence and metastasis of malignant tumors. However, the role of TRIM35 in breast cancer has thus far remained elusive. The expression of TRIM35 was examined in a bioinformatics database and the effects of TRIM35 on the malignant biological behavior of breast cancer were analyzed by Cell Counting Kit‑8, cell migration and invasion assays, flow cytometry and nude mouse xenograft experiments. It was determined that TRIM35 was downregulated in breast cancer tumor tissues and cell lines. Patients with low TRIM35 expression had shorter overall survival. Functional assays revealed that overexpression of TRIM35 inhibited the proliferation, migration and invasion, and promoted apoptosis of breast cancer cells. Furthermore, overexpression of TRIM35 was able to inhibit the Warburg effect in breast cancer cells. Mechanistic analyses indicated that TRIM35 regulates the transition of tetramers and dimers of pyruvate kinase M2 (PKM2) through ubiquitination and thereby affects the Warburg effect. In conclusion, the present results indicated that TRIM35 regulates the tetramer and dimer transition of PKM2 through ubiquitination and affects the malignant biological behavior of breast cancer by modulating the Warburg effect.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar
2	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and Farahmand L: Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI
4	Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breas cancer. Lancet. 365:1727–1741. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hatakeyama S: TRIM family proteins: Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhao G, Liu C, Wen X, Luan G, Xie L and Guo X: The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics. Pharmacol Ther. 227:1078812021. View Article : Google Scholar : PubMed/NCBI
7	Zhan W and Zhang S: TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets. Life Sci. 268:1189852021. View Article : Google Scholar : PubMed/NCBI
8	Meroni G: TRIM E3 ubiquitin ligases in rare genetic disorders. Adv Exp Med Biol. 1233:311–325. 2020. View Article : Google Scholar : PubMed/NCBI
9	Venuto S and Merla G: E3 ubiquitin ligase TRIM proteins, cell cycle and mitosis. Cells. 8:5102019. View Article : Google Scholar :
10	Goyani S, Roy M and Singh R: TRIM-NHL as RNA binding ubiquitin E3 ligase (RBUL): Implication in development and disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. Jan 6–2021.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
11	Connacher RP and Goldstrohm AC: Molecular and biological functions of TRIM-NHL RNA-binding proteins. Wiley Interdiscip Rev RNA. 12. pp. e16202021, View Article : Google Scholar
12	Eberhardt W, Haeussler K, Nasrullah U and Pfeilschifter J: Multifaceted roles of TRIM proteins in colorectal carcinoma. Int J Mol Sci. 21:75322020. View Article : Google Scholar :
13	Watanabe M and Hatakeyama S: TRIM proteins and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
14	Chen Z, Wang Z, Guo W, Zhang Z, Zhao F, Zhao Y, Jia D, Ding J, Wang H, Yao M and He X: TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the warburg effect and tumorigenicity in hepatocellular carcinoma. Oncogene. 34:3946–3956. 2015. View Article : Google Scholar
15	Wang R, Huang KL and Xing LX: TRIM35 functions as a novel tumor suppressor in breast cancer by inducing cell apoptosis through ubiquitination of PDK1. Neoplasma. 69:370–382. 2022. View Article : Google Scholar : PubMed/NCBI
16	Shulman RG and Rothman DL: The glycogen shunt maintains glycolytic homeostasis and the warburg effect in cancer. Trends Cancer. 3:761–767. 2017. View Article : Google Scholar : PubMed/NCBI
17	Lebelo MT, Joubert AM and Visagie MH: Warburg effect and its role in tumourigenesis. Arch Pharm Res. 42:833–847. 2019. View Article : Google Scholar : PubMed/NCBI
18	Kozal K, Jóźwiak P and Krześlak A: Contemporary perspectives on the warburg effect inhibition in cancer therapy. Cancer Control. Sep 23–2021.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
19	Johar D, Elmehrath AO, Khalil RM, Elberry MH, Zaky S, Shalabi SA and Bernstein LH: Protein networks linking warburg and reverse warburg effects to cancer cell metabolism. Biofactors. 47:713–728. 2021. View Article : Google Scholar : PubMed/NCBI
20	Zam W, Ahmed I and Yousef H: The warburg effect on cancer cells survival: The role of sugar starvation in cancer therapy. Curr Rev Clin Exp Pharmacol. 16:30–38. 2021. View Article : Google Scholar
21	Yu H, Zhao K, Zeng H, Li Z, Chen K, Zhang Z, Li E and Wu Z: N6-methyladenosine (m6A) methyltransferase WTAP accelerates the warburg effect of gastric cancer through regulating HK2 stability. Biomed Pharmacother. 133:1110752021. View Article : Google Scholar
22	Du Y, Wei N, Ma R, Jiang S and Song D: A miR-210-3p regulon that controls the warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer. Cell Death Dis. 11:7312020. View Article : Google Scholar
23	Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B and Liu P: NCAPD3 enhances warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer. J Exp Clin Cancer Res. 41:1982022. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
26	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
27	Dayton TL, Jacks T and Vander Heiden MG: PKM2, cancer metabolism, and the road ahead. EMBO Rep. 17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X and Peng C: Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 503:240–248. 2021. View Article : Google Scholar
29	Zhang Z, Deng X, Liu Y, Liu Y, Sun L and Chen F: PKM2, function and expression and regulation. Cell Biosci. 9:522019. View Article : Google Scholar : PubMed/NCBI
30	Zahra K, Dey T, Ashish, Mishra SP and Pandey U: Pyruvate kinase M2 and cancer: The role of PKM2 in promoting tumorigenesis. Front Oncol. 10:1592020. View Article : Google Scholar : PubMed/NCBI
31	He X, Du S, Lei T, Li X, Liu Y, Wang H, Tong R and Wang Y: PKM2 in carcinogenesis and oncotherapy. Oncotarget. 8:110656–110670. 2017. View Article : Google Scholar
32	Ikeda K and Inoue S: TRIM proteins as RING finger E3 ubiquitin ligases. Adv Exp Med Biol. 770:27–37. 2012. View Article : Google Scholar : PubMed/NCBI
33	Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, et al: Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 8:839–847. 2012. View Article : Google Scholar : PubMed/NCBI
34	Popovic D, Vucic D and Dikic I: Ubiquitination in disease pathogenesis and treatment. Nat Med. 20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI
35	Cockram PE, Kist M and Prakash S: Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 28:591–605. 2021. View Article : Google Scholar : PubMed/NCBI
36	Zou T and Lin Z: The involvement of ubiquitination machinery in cell cycle regulation and cancer progression. Int J Mol Sci. 22:57542021. View Article : Google Scholar : PubMed/NCBI
37	Senft D, Qi J and Ronai ZA: Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 18:69–88. 2018. View Article : Google Scholar :
38	Jia D, Wei L, Guo W, Zha R, Bao M, Chen Z, Zhao Y, Ge C, Zhao F, Chen T, et al: Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 54:1227–1236. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhang J, Xu Z and Yu B, Xu J and Yu B: Tripartite motif containing 35 contributes to the proliferation, migration, and invasion of lung cancer cells in vitro and in vivo. Biosci Rep. Apr 30–2020.Epub ahead of print.
40	Tan X, Cao F, Tang F, Lu C, Yu Q, Feng S, Yang Z, Chen S, He X, He J, et al: Suppression of DLBCL Progression by the E3 ligase Trim35 is mediated by CLOCK degradation and NK cell infiltration. J Immunol Res. 24:99958692021.
41	Liberti MV and Locasale JW: The warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
42	Lu Z and Hunter T: Metabolic kinases moonlighting as protein kinases. Trends Biochem Sci. 43:301–310. 2018. View Article : Google Scholar : PubMed/NCBI
43	Iqbal MA, Gupta V, Gopinath P, Mazurek S and Bamezai RN: Pyruvate kinase M2 and cancer: An updated assessment. FEBS Lett. 588:2685–2692. 2014. View Article : Google Scholar : PubMed/NCBI
44	Li Z, Yang P and Li Z: The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
45	Wong N, Ojo D, Yan J and Tang D: PKM2 contributes to cancer metabolism. Cancer Lett. 356:184–191. 2015. View Article : Google Scholar
46	Zheng M, Xing W, Liu Y, Li M and Zhou H: Tetramerization of SATB1 is essential for regulating of gene expression. Mol Cell Biochem. 430:171–178. 2017. View Article : Google Scholar : PubMed/NCBI
47	French AC, Luscher B and Litchfield DW: Development of a stabilized form of the regulatory CK2beta subunit that inhibits cell proliferation. J Biol Chem. 282:29667–29677. 2007. View Article : Google Scholar : PubMed/NCBI